335504762021042320220531
1434-472627852021MayEuropean archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck SurgeryEur Arch OtorhinolaryngolLncRNA FEZF1-AS1 accelerates the migration and invasion of laryngeal squamous cell carcinoma cells through miR-4497 targeting GBX2.152315351523-153510.1007/s00405-021-06636-5MiR-4497 has been previously proved to exert an anti-cancer role in laryngeal squamous cell carcinoma (LSCC) by negatively regulating gastrulation brain homeobox 2 (GBX2). However, the mechanism of miR-4497 in LSCC has yet to be fully elucidated. This study intended to investigate the role of FEZF1-AS1 in the migration and invasion of LSCC cells and clarified its mechanism through miR-4497 and GBX2.qPCR evaluated the expression of FEZF1-AS1, miR-4497 and GBX2 in LSCC tissues and cells, compared with controls. Western blotting analyzed GBX2, E-cadherin, N-cadherin and Vimentin. CCK8, wound healing and transwell assays assessed the viability, migration and invasion of TU686 and UM-SCC-17A cells. Luciferase reporter assay affirmed the interplay of miR-4497 with FEZF1-AS1 or GBX2 and Pearson's correlation analysis explored the association between each two genes in both tumor and non-tumor tissues.FEZF1-AS1 was highly expressed in LSCC tissues and cells. Silence or elevation of FEZF1-AS1 inhibited or promoted the migration and invasion of TU686 and UM-SCC-17A cells. FEZF1-AS1 targeted and negatively modulated miR-4497. Inhibition of miR-4497 markedly restored the FEZF1-AS1 silence-repressed cell viability of TU686 and UM-SCC-17A cells. Further, FEZF1-AS1 could positively regulate GBX2 via negative regulation of miR-4497. In these two cells, GBX2 deficiency reversed the promoting impacts of miR-4497 repression on migration and invasion.Taken together, FEZF1-AS1, heightened in LSCC tissues and cells, promotes cell migration and invasion of LSCC cells via targeting miR-4497 that inhibits GBX2. The finding may offer new options for the treatment of this cancer.ChenXudongX0000-0002-1673-4696Department of Otolaryngology, First Hospital of Ningbo City, Ningbo, Zhejiang, 315000, People's Republic of China. chenxudong_xdc@163.com.ChengPengPDepartment of Otolaryngology, First Hospital of Ningbo City, Ningbo, Zhejiang, 315000, People's Republic of China.HuCihaoCDepartment of Otolaryngology, First Hospital of Ningbo City, Ningbo, Zhejiang, 315000, People's Republic of China.eng2020360873the Medical and Health Project of Zhejiang ProvinceJournal Article20210207
GermanyEur Arch Otorhinolaryngol90029370937-44770GBX2 protein, human0Homeodomain Proteins0MIRN4497 microRNA, human0MicroRNAs0RNA, Long NoncodingIMCell ProliferationHead and Neck NeoplasmsHomeodomain ProteinsHumansMicroRNAsgeneticsRNA, Long NoncodingSquamous Cell Carcinoma of Head and NeckgeneticsFEZF1-AS1GBX2InvasionLaryngeal squamous cell carcinomaMigrationmiR-4497202010142021120202128602021424602021272052ppublish3355047610.1007/s00405-021-06636-510.1007/s00405-021-06636-5Zhang X, Cavus O, Zhou Y, Dusitkasem S (2018) Airway management during anesthetic induction of secondary laryngectomy for recurrent laryngeal cancer: three cases of report and analysis. Front Med 5:264. https://doi.org/10.3389/fmed.2018.0026410.3389/fmed.2018.00264Mosca L, Minopoli M, Pagano M, Vitiello F, Carriero MV, Cacciapuoti G, Porcelli M (2020) Effects of S-adenosyl-L-methionine on the invasion and migration of head and neck squamous cancer cells and analysis of the underlying mechanisms. Int J Oncol 56(5):1212–1224. https://doi.org/10.3892/ijo.2020.501110.3892/ijo.2020.5011323195797115356Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A (2018) Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA 68(6):394–424. https://doi.org/10.3322/caac.2149210.3322/caac.2149230207593Steuer CE, El-Deiry M, Parks JR, Higgins KA, Saba NF (2017) An update on larynx cancer. CA 67(1):31–50. https://doi.org/10.3322/caac.2138610.3322/caac.2138627898173Khan JA, Siddque MA, Haque MN, Kundu SC, Ahmed MU, Bhuiyan AS (2015) Etiology of laryngeal squamous cell carcinoma: study of 50 cases in Mymensingh Medical College Hospital. MMJ 24(3):492–49626329945Escalante P, Barría T, Cancino M, Rahal M, Cerpa L, Sandoval C, Molina-Mellico S, Suárez M, Martínez M, Cáceres DD, Quiñones LA, Varela NM (2020) Genetic polymorphisms as non-modifiable susceptibility factors to laryngeal cancer. Biosci Rep. https://doi.org/10.1042/bsr2019118810.1042/bsr20191188323382787201556Chu YL (2020) Circ_0067934 correlates with poor prognosis and promotes laryngeal squamous cell cancer progression by sponging miR-1324. Eur Rev Med Pharmacol Sci 24(8):4320–4327. https://doi.org/10.26355/eurrev_202004_2101310.26355/eurrev_202004_2101332373969Zhao R, Tian L, Zhao B, Sun Y, Cao J, Chen K, Li F, Li M, Shang D, Liu M (2020) FADS1 promotes the progression of laryngeal squamous cell carcinoma through activating AKT/mTOR signaling. Cell Death Dis 11(4):272. https://doi.org/10.1038/s41419-020-2457-510.1038/s41419-020-2457-5323326987181692Cao G, Cui R, Liu C, Zhang Z (2019) MicroRNA regulation of transthyretin in trophoblast biofunction and preeclampsia. Arch Biochem Biophys 676:108129. https://doi.org/10.1016/j.abb.2019.10812910.1016/j.abb.2019.10812931593646Cao M, Song F, Yang X, Peng L, Cheng Y, Zheng Q, Liang Y, Wang C (2019) Identification of potential long noncoding RNA biomarker of Mercury compounds in Zebrafish embryos. Chem Res Toxicol 32(5):878–886. https://doi.org/10.1021/acs.chemrestox.9b0002910.1021/acs.chemrestox.9b0002930912647Liu Y, Yang Y, Li L, Liu Y, Geng P, Li G, Song H (2018) LncRNA SNHG1 enhances cell proliferation, migration, and invasion in cervical cancer. Biochem Cell Biol 96(1):38–43. https://doi.org/10.1139/bcb-2017-018810.1139/bcb-2017-018828930646Wei GH, Wang X (2017) lncRNA MEG3 inhibit proliferation and metastasis of gastric cancer via p53 signaling pathway. Eur Rev Med Pharmacol Sci 21(17):3850–385628975980Xu Z, Xi K (2019) LncRNA RGMB-AS1 promotes laryngeal squamous cell carcinoma cells progression via sponging miR-22/NLRP3 axis. Biomed Pharmacother 118:109222. https://doi.org/10.1016/j.biopha.2019.10922210.1016/j.biopha.2019.10922231351424Bian Z, Zhang J, Li M, Feng Y, Wang X, Zhang J, Yao S, Jin G, Du J, Han W, Yin Y, Huang S, Fei B, Zou J, Huang Z (2018) LncRNA-FEZF1-AS1 promotes tumor proliferation and metastasis in colorectal cancer by regulating PKM2 signaling. Clin Cancer Res 24(19):4808–4819. https://doi.org/10.1158/1078-0432.ccr-17-296710.1158/1078-0432.ccr-17-29672991489429914894Liu YW, Xia R, Lu K, Xie M, Yang F, Sun M, De W, Wang C, Ji G (2017) LincRNAFEZF1-AS1 represses p21 expression to promote gastric cancer proliferation through LSD1-Mediated H3K4me2 demethylation. Mol Cancer 16(1):39. https://doi.org/10.1186/s12943-017-0588-910.1186/s12943-017-0588-9282091705314465Zhao X, Cheng Z, Wang J (2018) Long Noncoding RNA FEZF1-AS1 Promotes proliferation and inhibits apoptosis in ovarian cancer by activation of JAK-STAT3 pathway. Med Sci Monit 24:8088–8095. https://doi.org/10.12659/msm.91119410.12659/msm.911194304161946243867Yang L, Ye Y, Chu J, Jia J, Qu Y, Sun T, Yin H, Ming L, Wan J, He F (2019) Long noncoding RNA FEZF1-AS1 promotes the motility of esophageal squamous cell carcinoma through Wnt/β-catenin pathway. Cancer Manag Res 11:4425–4435. https://doi.org/10.2147/cmar.s19600410.2147/cmar.s196004311910056525003Sun FB, Lin Y, Li SJ, Gao J, Han B, Zhang CS (2018) MiR-210 knockdown promotes the development of pancreatic cancer via upregulating E2F3 expression. Eur Rev Med Pharmacol Sci 22(24):8640–8648. https://doi.org/10.26355/eurrev_201812_1662810.26355/eurrev_201812_1662830575904Fan Z, Cui H, Xu X, Lin Z, Zhang X, Kang L, Han B, Meng J, Yan Z, Yan X, Jiao S (2015) MiR-125a suppresses tumor growth, invasion and metastasis in cervical cancer by targeting STAT3. Oncotarget 6(28):25266–25280. https://doi.org/10.18632/oncotarget.445710.18632/oncotarget.4457263896814694830Chen X, Zhang L, Tang S (2019) MicroRNA-4497 functions as a tumor suppressor in laryngeal squamous cell carcinoma via negatively modulation the GBX2. Auris Nasus Larynx 46(1):106–113. https://doi.org/10.1016/j.anl.2018.05.00510.1016/j.anl.2018.05.00529843929Liao Y, Luo H, He Z, Kuang Y, Chen P, Zhang X, Chen J, Wen Q, Xie Y, Ding S (2019) A Combination of UTMD-mediated HIF-1α shRNA transfection and TAE in the treatment of hepatic cancer. Biomed Res Int 2019:1937460. https://doi.org/10.1155/2019/193746010.1155/2019/1937460309115406399560Thomson DW, Dinger ME (2016) Endogenous microRNA sponges: evidence and controversy. Nat Rev Genet 17(5):272–283. https://doi.org/10.1038/nrg.2016.2010.1038/nrg.2016.2027040487Tay Y, Rinn J, Pandolfi PP (2014) The multilayered complexity of ceRNA crosstalk and competition. Nature 505(7483):344–352. https://doi.org/10.1038/nature1298610.1038/nature1298641134814113481Han Y, Hu H, Zhou J (2019) Knockdown of LncRNA SNHG7 inhibited epithelial-mesenchymal transition in prostate cancer though miR-324-3p/WNT2B axis in vitro. Pathol Res Pract 215(10):152537. https://doi.org/10.1016/j.prp.2019.15253710.1016/j.prp.2019.15253731324390Li M, Wang Q, Xue F, Wu Y (2019) lncRNA-CYTOR works as an oncogene through the CYTOR/miR-3679-5p/MACC1 axis in colorectal cancer. DNA Cell Biol 38(6):572–582. https://doi.org/10.1089/dna.2018.454810.1089/dna.2018.454831144988Fang Y, Yuan Y, Zhang LL, Lu JW, Feng JF, Hu SN (2018) Downregulated GBX2 gene suppresses proliferation, invasion and angiogenesis of breast cancer cells through inhibiting the Wnt/β-catenin signaling pathway. Cancer Biomark 23(3):405–418. https://doi.org/10.3233/cbm-18146610.3233/cbm-18146630223390Gao AC, Lou W, Isaacs JT (2000) Enhanced GBX2 expression stimulates growth of human prostate cancer cells via transcriptional up-regulation of the interleukin 6 gene. Clin Cancer Res 6(2):493–49710690529Xia Y, Tang G, Wang C, Zhong J, Chen Y, Hua L, Li Y, Liu H, Zhu B (2020) Functionalized selenium nanoparticles for targeted siRNA delivery silence Derlin1 and promote antitumor efficacy against cervical cancer. Drug Deliv 27(1):15–25. https://doi.org/10.1080/10717544.2019.166745210.1080/10717544.2019.166745231830840